A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma
- Conditions
- Intrahepatic CholangiocarcinomaMachine Learning
- Interventions
- Procedure: lymph nodes dissection
- Registration Number
- NCT06290739
- Lead Sponsor
- West China Hospital
- Brief Summary
The object of this study is to develop a model for prediction of lymph node metastasis among intrahepatic cholangiocarcinoma (ICC) patients. Intrahepatic cholangiocarcinoma is the second most common kind of primary liver cancer, accounting for approximately 10%-15%. There is a lack of agreement regarding the necessity of performing lymph node dissection (LND) in patients with ICC. Currently, the percentage of LND is below 50%, and the rate of sufficient LND (≥6) has plummeted to less than 20%. Consequently, a large proportion of patients are unable to acquire LN status, which hinders the following systematic treatment strategies after surgery:. Therefore, our objective is to construct a LN metastasis model utilizing machine learning techniques, including patients' clinical data and pathology information, with the goal of offering a reference for patients who have not undergone LND or have had inadequate LND.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 483
- 1.Patients who were confirmed with intrahepatic cholangiocarcinoma 2. curative-intent hepatectomy 3. Without concurrent extrahepatic disease
- 1.Patients lacking complete pathology information, 2. Patients who didn't get curative resection 3.Patients with concurrent extrahepatic disease or had missing follow-up data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Intrahepatic cholangiocarcinoma patients who underwent lymph nodes dissection lymph nodes dissection -
- Primary Outcome Measures
Name Time Method Overall survival 2010.01-2019.01 Overall survival (OS) refers to the duration between the commencement of surgery and the patient's demise due to any reason.
- Secondary Outcome Measures
Name Time Method Disease free survival 2010.01-2019.01 Disease-free survival (DFS) refers to the period of time from the date of surgery until the occurrence of a relapse either within or outside the liver.
Trial Locations
- Locations (1)
Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University
🇨🇳Chengdu, Sichuan, China